pyrazines has been researched along with Carcinoma, Small Cell in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 9 (90.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bunn, PA | 1 |
| Edelman, MJ | 1 |
| Bold, RJ; Davies, AM; Gandara, DG; Lara, PN; Mortenson, MM; Schlieman, MG; Virudachalam, S | 1 |
| Aggarwal, BB; Gutierrez, AM; Lotan, R; Shishodia, S | 1 |
| Schenkein, DP | 1 |
| Bold, RJ; Davies, AM; Gandara, DR; Gumerlock, PH; Lara, PN; Mack, PC | 1 |
| Scagliotti, G | 1 |
| Atkins, JN; Chansky, K; Crowley, JJ; Davies, AM; Farneth, N; Franklin, WA; Gandara, DR; Guaglianone, PP; Gumerlock, PH; Lara, PN; Mack, PC | 1 |
| Fujita, M; Higashino, K; Tsuchida, T | 1 |
| Balcerzak, SP; Galloway, S; Kraut, EH; Moore, T; Thomas, JP; Vandre, DD | 1 |
4 review(s) available for pyrazines and Carcinoma, Small Cell
| Article | Year |
|---|---|
The potential role of proteasome inhibitors in the treatment of lung cancer.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Cycle; Clinical Trials as Topic; Humans; Lung Neoplasms; Protease Inhibitors; Pyrazines | 2004 |
Preclinical data with bortezomib in lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Drug Interactions; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Protease Inhibitors; Pyrazines; Tumor Cells, Cultured | 2005 |
Proteasome inhibition in small-cell lung cancer: preclinical rationale and clinical applications.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Small Cell; Clinical Trials as Topic; Humans; Lung Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Ubiquitin | 2005 |
Proteasome inhibitors in lung cancer.
Topics: Animals; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Humans; Lung Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2006 |
2 trial(s) available for pyrazines and Carcinoma, Small Cell
| Article | Year |
|---|---|
Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327).
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Carcinoma, Small Cell; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Infusions, Intravenous; Lung Neoplasms; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Probability; Pyrazines; Remission Induction; Risk Assessment; Survival Analysis | 2006 |
A phase II study of CI-980 in previously untreated extensive small cell lung cancer: an Ohio State University phase II research consortium study.
Topics: Adult; Aged; Antineoplastic Agents; Carbamates; Carcinoma, Small Cell; Female; Humans; Leukocyte Count; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutrophils; Pyrazines; Pyridines | 2002 |
4 other study(ies) available for pyrazines and Carcinoma, Small Cell
| Article | Year |
|---|---|
Lung cancer - Second Annual Winter Conference.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Structure; Paclitaxel; Pyrazines; Quinazolines | 2005 |
Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer.
Topics: Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Small Cell; Gene Expression Regulation, Neoplastic; Humans; Luciferases; Lung Neoplasms; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Signal Transduction; Transcription, Genetic; Tumor Cells, Cultured | 2005 |
N-(4-hydroxyphenyl)retinamide inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of I(kappa)B(alpha) kinase and nuclear factor-kappaB-regulated gene products.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Small Cell; Carrier Proteins; Cell Growth Processes; Cyclin D1; Cyclooxygenase 2; Down-Regulation; Drug Synergism; Enzyme Activation; Fenretinide; Genes, myc; Humans; I-kappa B Kinase; I-kappa B Proteins; Lung Neoplasms; Membrane Glycoproteins; NF-kappa B; NF-KappaB Inhibitor alpha; Oncogene Protein v-akt; Osteoclasts; Phosphorylation; Promoter Regions, Genetic; Proto-Oncogene Proteins c-myc; Pyrazines; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Transcription Factor RelA; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2005 |
Effect of vesnarinone in combination with anti-cancer drugs on lung cancer cell lines.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cell Division; Cisplatin; Coloring Agents; Deoxycytidine; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Flow Cytometry; Gemcitabine; Humans; Lung Neoplasms; Pyrazines; Quinolines; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 1999 |